Abnormal Estrogen Conjugation in Women at Risk for Familial Breast Cancer at the Periovulatory Stage of the Menstrual Cycle1

Total Page:16

File Type:pdf, Size:1020Kb

Abnormal Estrogen Conjugation in Women at Risk for Familial Breast Cancer at the Periovulatory Stage of the Menstrual Cycle1 [CANCER RESEARCH 43,1884-1890, April 1983] 0008-5472/83/0043-0000$02.00 Abnormal Estrogen Conjugation in Women at Risk for Familial Breast Cancer at the Periovulatory Stage of the Menstrual Cycle1 Jack Fishman,2 H. Leon Bradlow, David K. Fukushima, John O'Connor, Robert S. Rosenfeld, G. Jay Graepel, Robert Elston,3 and Henry Lynch The Rocketeller University. New York. New York 10021 ¡J.F.. H. L. B.¡;Montefiore Hospital and Medical Center, Bronx. New York 10467 [D. K. F., J. 0., R. S. R.]; E. I. du Pont de Nemours, Wilmington, Delaware 19898 [G. J. G.]; Louisiana State University Medical Center, New Orleans, Louisiana 70112 [R. E.J; and Creighton University, Omaha, Nebraska 68178 [H. L] ABSTRACT A number of such studies have been carried out on the population of the Isle of Guernsey, and the results to date have The present study was designed to establish whether women suggested the existence of endocrine differences residing prin with a family history of breast cancer exhibit endocrine abnor cipally in the androgenic hormones which appear to correlate malities which could be responsible for their increased risk for with increased risk for breast cancer (4, 5). Because these the disease. Plasma hormone levels were measured every sec studies were carried out on a very large heterogeneous popula ond day throughout the menstrual cycle in 30 women at risk for tion, an extensive library of hormones and their daily changing familial breast cancer and in an equal number of matched con levels during the menstrual cycle could not be assessed. Even trols. Thirteen of the 14 substances measured exhibited no now, detailed studies on a population large enough to yield a differences between the two populations, but plasma androster- meaningful number of positive cases would be prohibitive in one sulfate was significantly lower in the high-risk subjects. terms of time and effort. Therefore, a more realistic prospective Thirteen urinary hormones were measured every day throughout in-depth study would require a small select population of individ the cycle with only the mean estrone and estradiol glucuronide uals known to be at high risk for breast cancer which could be but not estriol glucuronide content being significantly lower in compared to a matched group of normal-risk women. Studies of the high-risk subjects. A compensatory increase in the urinary this type which have used racial or ethnic high- and low-risk estrogen sulfates was observed. Daily analysis of these differ populations can be faulted because the risks may incorporate ences showed that they were most pronounced in the periovu- environmental factors which may not be reflected in any endo latory period of the cycle. These results suggest that the genetic crine disturbances. Also, the environmental influences may alter risk for breast cancer is associated with an abnormality in the endocrine milieu in directions unrelated to breast cancer risk. estrogen conjugation at a specific time of the ovulatory cycle. Indeed, several such studies of endocrine differences between high- and low-risk racial groups have produced contradictory INTRODUCTION results (10, 32). One of the most secure epidemiological observations in breast The participation of endocrine factors in the etiology of human cancer is that a family history of the disease very significantly breast cancer is supported by several lines of evidence. These increases the risk for it (1, 23, 26). This makes a population at include a series of epidemiological studies and the well-charac genetic risk for breast cancer a particularly suitable group in terized impact of endocrine manipulation on the onset and prog which to attempt to identify hormonal factors which could be ress of the disease in animals and humans. Intensive efforts involved in the increased risk for the disease. Comparative have been devoted to identifying specific endocrine differences studies of such high-risk and low-risk women eliminate the between women with the disease and unaffected controls which question of environmental impact when these groups are could be involved in the disease process (2, 11, 15-17, 21, 25, matched also for geographic location, as well as dietary and 28, 29). Few, if any, clear-cut differences have been securely behavioral patterns. It is clear that any endocrine differences identified to date, and even these are subject to uncertainty as noted in such studies may represent factors which are associ to whether they were present prior to the disease or were a ated only with the risk for familial breast cancer and need not consequence of the illness. Furthermore, available epidemiolog necessarily apply to the population at large. Moreover, it is ical evidence suggests that it is the endocrine milieu in the early reproductive years of a woman's life which determines the risk certainly possible that endocrine abnormalities observed in our high-risk population may be overridden by other environmental of the development of breast cancer many years later (18), so factors in the population at large. It is, however, possible that that endocrine studies carried out after the diagnosis of the the individuals at genetic risk for breast cancer could constitute cancer could be irrelevant or even misleading insofar as the an enriched pool of endocrine abnormalities which could be endocrine role in the onset of the disease is concerned. These factors in nonfamilial disease as well. Therefore, disturbances in considerations have directed attention to prospective studies in endocrine profiles in a population at risk for familial breast cancer which endocrine profiles, obtained a considerable time prior to which are not present in a matched group free of genetic risk for the emergence of the disease, can be related to its subsequent the disease could provide leads to specific endocrine features incidence. linked to the incidence of breast cancer in all individuals. Such 1Supported by Grant CA 22795 from the National Cancer Institute. differences could provide a way of identifying women at risk for 2 To whom requests for reprints should be addressed, at The Rockefeller the disease and, more importantly, offer insight into the mecha University, 1230 York Avenue, New York. N. Y. 10021. 3 Recipient of Grant CA 28198 from the National Cancer Institute nisms of hormonal participation in the oncogenic process. Received August 19,1982; accepted December 10, 1982. Preliminary results of such an in-depth study in which hormonal 1884 CANCER RESEARCH VOL. 43 Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 1983 American Association for Cancer Research. Estrogen Metabolism in Women at Risk for Breast Cancer Table 1 Matching of high- and low-risk population statistics Ofpairs3030302130303030Case case-controldifference0.23 mean1943.9712.331.7721.6727.3313.73137.5765.60Controlmean1943.7312.732.3721.6726.7313.20128.9764.70Mean Birth date(yr)Menarche ±0.44"-0.36 (yr)ParityAge ±0.36-0.60 ±0.320.00 atfirstpregnancy(yr)Cycle ±0.290.60 length(days)UH ±0.850.53 peak(days)Wt ±0.968.60 (Ib)HI ±3.490.83 (inches)" ±0.53t0.55-1.01-1.870.000.700.552.461.57PNS"NSNSNSNSNS<0.05NS S.E."Mean ± NS. not significant.NO. levels throughout the menstrual cycle in 30 young women at an area as close as possible to the matching subject to avoid any high risk for familial breast cancer were compared with 30 possible microenvironmental effects. To avoid any possibility of seasonal matched controls have already been reported (13, 14). No sig changes, each subject and control pair was studied at the same time. nificant differences between these populations were observed in As shown in Table 1, the matching of the 2 populations for all of these the plasma levels of either prolactin, LH," FSH, estrone, estradiol, parameters was extremely close except for body weight where a small difference existed. Although the high-risk subjects were on average 3.97 or estriol at any stage of the menstrual cycle, although a con kg heavier than the controls, this is too small an amount to result in sistent trend toward lower values in all of these, except estriol, significant endocrine changes (12), particularly since it has been sug was noted in the high-risk populations (14). Analysis of urinary gested that height rather than weight is the more critical risk factor (9). metabolites, on the other hand, revealed highly significant differ Furthermore, our data show no correlation between body weight and ences in estrone and estradiol glucuronides, with the high-risk any of the significant hormonal differences observed, indicating that this individuals excreting lower amounts of these metabolites than matching factor had no influence on the results. Blood samples (15 ml) the controls (13). We now present further results from this study were obtained at the same time on alternate mornings from the start of which include differences in urinary estrone sulfate and in plasma one menstrual cycle to the start of the next cycle by a visiting nurse. Blood samples were promptly centrifuged, and the plasma samples were androsterone sulfate content. The temporal relationship of the kept at -20° until the analyses were carried out. Following careful various hormonal differences to the stages of the menstrual instructions, all subjects collected 12-hr urine samples (7 p.m. to 7 a.m.) cycle is also analyzed and discussed. These results provide every day starting from the cessation of one menstrual cycle to the compelling evidence that women at risk for familial breast cancer beginning of the next. On one day in the follicular phase and one day in display an abnormality in their metabolism of estradiol which is the luteal phase, a complete 24-hr urine collection was obtained to serve centered at the periovulatory period.
Recommended publications
  • Estrone Sulfate
    Available online at www.sciencedirect.com Journal of Steroid Biochemistry & Molecular Biology 109 (2008) 158–167 Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa)ଝ Frank Giton a,∗, Alexandre de la Taille b, Yves Allory b, Herve´ Galons c, Francis Vacherot b, Pascale Soyeux b, Claude Clement´ Abbou b, Sylvain Loric b, Olivier Cussenot b, Jean-Pierre Raynaud d, Jean Fiet b a AP-HP CIB INSERM IMRB U841eq07, Henri Mondor, Facult´edeM´edecine, 94010 Cr´eteil, France b INSERM IMRB U841 eq07, CHU Henri Mondor, Facult´edeM´edecine, 94010 Cr´eteil, France c Service de Chimie organique, Facult´e de Pharmacie Paris V, 75006 Paris, France d Universit´e Pierre et Marie Curie, 75252 Paris, France Received 26 December 2006; accepted 26 October 2007 Abstract Seeking insight into the possible role of estrogens in prostate cancer (PCa) evolution, we assayed serum E2, estrone (E1), and estrone sulfate (E1S) in 349 PCa and 100 benign prostatic hyperplasia (BPH) patients, and in 208 control subjects in the same age range (50–74 years). E1 (pmol/L ± S.D.) and E1S (nmol/L ± S.D.) in the PCa and BPH patients (respectively 126.1 ± 66.1 and 2.82 ± 1.78, and 127.8 ± 56.4 and 2.78 ± 2.12) were significantly higher than in the controls (113.8 ± 47.6 and 2.11 ± 0.96). E2 was not significantly different among the PCa, BPH, and control groups. These assays were also carried out in PCa patients after partition by prognosis (PSA, Gleason score (GS), histological stage, and surgical margins (SM)).
    [Show full text]
  • 01 Front.Pdf
    Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author. STUDIES TOWARDS THE DEVELOPMENT OF A MULTI­ PURPOSE HOME SELF-TEST KIT FOR THE DETECTION OF URINARY TETRAHYDROCORTISONE AND TESTOSTERONE METABOLITES A thesis submitted in partial fulfilment of the requirements for the degree of Master of Science in Chemistry at Massey University Claire Margaret Nielsen 2003 ii Abstract The development of homogeneous enzyme immunoassays (HEIA) for testosterone glucuronide (TG) and tetrahydrocortisone glucuronide (THEG) in urine are described. The proposed test system is based on the Ovarian Monitor homogeneous immunoassay system, established by J.B Brown and L.F. Blackwell et al. 1 as a simple, laboratory accurate, monitoring device for the measurement of estrone glucuronide (E1G) and pregnanediol glucuronide (PdG) as markers of the fertile phase during a womans menstrual cycle. This information can be used readily by women to identify their cyclical periods of fertility and infertility. The major testosterone metabolite in the urine of males, testosterone p-glucuronide, was synthesised by firstly preparing the glycosyl donor a-bromosugar and conjugating this with testosterone under standard Koenigs-Knorr conditions. 1H nmr studies confirmed that the synthetic steroid glucuronide had the same stereochemistry as the naturally occurring urinary testosterone glucuronide. Testosterone glucuronide and tetrahydrocortisone glucuronide conjugates of hen egg white lysozyme were prepared using the active ester coupling method in good yield. Unreacted lysozyme was successfully removed from the reaction mixture by a combination of cation­ exchange chromatography in 7 M urea and hydrophobic-interaction chromatography.
    [Show full text]
  • Comprehensive Urinary Hormone Assessments
    ENDOCRINOLOGY Complete Hormones – Analytes Comprehensive Urinary Hormone Assessments Urinary Pregesterones Urinary Glucocorticoids Urinary Androgens Urinary Estrogens Pregnanediol Cortisol, Free Testosterone Estrone Pregnanetriol Total 17-Hydroxy-corticosteroids Dehydroepiandrosterone (DHEA) Estradiol allo-Tetrahydrocortisol, a-THF Total 17-Ketosteroids Estriol Tetrahydrodeoxycortisol Androsterone 2-Hydroxyestrone Tetrahydrocortisol, THF Etiocholanolone 2-Methoxyestrone Tetrahydrocortisone, THE 11-Keto-androsterone 4-Hydroxyestrone 17-Hydroxysteriods, Total 11-Keto-etiocholanolone 4-Methoxyestrone Pregnanetriol 11-Hydroxy-androsterone 16α-Hydroxyestrone 11-Hydroxy-etiocholanolone 2-Hydroxy-estrone:16α-Hydroxyestrone ratio 2-Methoxyestrone:2-Hydroxyestrone ratio CLINICIAN INFORMATION 4-Methoxyestrone:4-Hydroxyestrone ratio ADVANCING THE CLINICAL UTILITY OF URINARY HORMONE ASSESSMENT Specimen Requirements Complete Hormones™ is Genova’s most comprehensive • 120 ml aliquot, refrigerated until shipped, urinary hormone profile, and is designed to assist with the from either First Morning Urine or 24-Hour clinical management of hormone-related symptoms. This profile Collection Why Use Complete Hormones? assesses parent hormones and their metabolites as well as key metabolic pathways, and provides insight into the contribution Hormone testing is an effective tool for assessing Related Profiles: that sex hormones may have in patients presenting with and managing patients with hormone- related symptoms. This profile supports: • Male Hormonal Health™
    [Show full text]
  • The Metabolism of Anabolic Agents in the Racing Greyhound
    The Metabolism of Anabolic Agents In the Racing Greyhound A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor of Philosophy by Mr. Keith Robert Williams, B.Sc. July 1999 Department of Forensic Medicine & Science University of Glasgow Copyright © 1999 by Keith R. Williams. All rights reserved. No part o f this thesis may be reproduced in any forms or by any means without the written permission o f the author. I ProQuest Number: 13833925 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13833925 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 GLASGOW UNIVERSITY LIBRARY 111-X (coK To my parents for all their help, support and encouragement i Table of Contents i List of Figures V List of Tables VIII Summary IX Chapter 1: Drugs in Sport ...............................................................................................................................1 Introduction .................................................................................................................................................
    [Show full text]
  • Alteration of the Steroidogenesis in Boys with Autism Spectrum Disorders
    Janšáková et al. Translational Psychiatry (2020) 10:340 https://doi.org/10.1038/s41398-020-01017-8 Translational Psychiatry ARTICLE Open Access Alteration of the steroidogenesis in boys with autism spectrum disorders Katarína Janšáková 1, Martin Hill 2,DianaČelárová1,HanaCelušáková1,GabrielaRepiská1,MarieBičíková2, Ludmila Máčová2 and Daniela Ostatníková1 Abstract The etiology of autism spectrum disorders (ASD) remains unknown, but associations between prenatal hormonal changes and ASD risk were found. The consequences of these changes on the steroidogenesis during a postnatal development are not yet well known. The aim of this study was to analyze the steroid metabolic pathway in prepubertal ASD and neurotypical boys. Plasma samples were collected from 62 prepubertal ASD boys and 24 age and sex-matched controls (CTRL). Eighty-two biomarkers of steroidogenesis were detected using gas-chromatography tandem-mass spectrometry. We observed changes across the whole alternative backdoor pathway of androgens synthesis toward lower level in ASD group. Our data indicate suppressed production of pregnenolone sulfate at augmented activities of CYP17A1 and SULT2A1 and reduced HSD3B2 activity in ASD group which is partly consistent with the results reported in older children, in whom the adrenal zona reticularis significantly influences the steroid levels. Furthermore, we detected the suppressed activity of CYP7B1 enzyme readily metabolizing the precursors of sex hormones on one hand but increased anti-glucocorticoid effect of 7α-hydroxy-DHEA via competition with cortisone for HSD11B1 on the other. The multivariate model found significant correlations between behavioral indices and circulating steroids. From dependent variables, the best correlation was found for the social interaction (28.5%). Observed changes give a space for their utilization as biomarkers while reveal the etiopathogenesis of ASD.
    [Show full text]
  • Insulin Enhances ACTH-Stimulated Androgen and Glucocorticoid Metabolism in Hyperandrogenic Women
    European Journal of Endocrinology (2011) 164 197–203 ISSN 0804-4643 CLINICAL STUDY Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women Flavia Tosi, Carlo Negri, Elisabetta Brun, Roberto Castello, Giovanni Faccini1, Enzo Bonora, Michele Muggeo, Vincenzo Toscano2 and Paolo Moghetti Division of Endocrinology and Metabolism and 1Clinical Chemistry Laboratory, University and Azienda Integrata Ospedaliera Universitaria di Verona, P.le Stefani 1, 37126 Verona, Italy and 2Division of Endocrinology, Ospedale Sant’Andrea, University La Sapienza, Ospedale Sant’Andrea, Via Di Grotta Rossa 1035, 00189 Rome, Italy (Correspondence should be addressed to P Moghetti; Email: [email protected]) Abstract Objective: In hyperandrogenic women, hyperinsulinaemia amplifies 17a-hydroxycorticosteroid intermediate response to ACTH, without alterations in serum cortisol or androgen response to stimulation. The aim of the study is to assess whether acute hyperinsulinaemia determines absolute changes in either basal or ACTH-stimulated adrenal steroidogenesis in these subjects. Design and methods: Twelve young hyperandrogenic women were submitted in two separate days to an 8 h hyperinsulinaemic (80 mU/m2!min) euglycaemic clamp, and to an 8 h saline infusion. In the second half of both the protocols, a 4 h ACTH infusion (62.5 mg/h) was carried out. Serum cortisol, progesterone, 17a-hydroxyprogesterone (17-OHP), 17a-hydroxypregnenolone (17-OHPREG), DHEA and androstenedione were measured at basal level and during the protocols. Absolute adrenal hormone secretion was quantified by measuring C19 and C21 steroid metabolites in urine collected after the first 4 h of insulin or saline infusion, and subsequently after 4 h of concurrent ACTH infusion. Results: During insulin infusion, ACTH-stimulated 17-OHPREG and 17-OHP were significantly higher than during saline infusion.
    [Show full text]
  • The Relationship Between Serum Sex Steroid Levels and Heart Rate Variability Parameters in Males and the Effect Of
    Türk Kardiyol Dern Arş - Arch Turk Soc Cardiol 2010;38(7):459-465 459 The relationship between serum sex steroid levels and heart rate variability parameters in males and the effect of age Erkeklerde serum cinsiyet steroidleri ile kalp hızı değişkenliği verileri arasındaki ilişki ve yaşın etkileri M. Tolga Doğru, M.D., M. Murad Başar, M.D.,# Ercan Yuvanç, M.D.,# Vedat Şimşek, M.D., Ömer Şahin, M.D. Departments of Cardiology and #Urology, Medicine Faculty of Kırıkkale University, Kırıkkale Objectives: We evaluated the relationships between sex Amaç: Bu çalışmada cinsiyet steroidleri ile kalp hızı de- steroid levels and heart rate variability (HRV) parameters. ğişkenliği (KHD) verileri arasındaki ilişkiler araştırıldı. Study design: The study included 114 male subjects (mean Çalışma planı: Çalışmaya, kardiyolojik açıdan değerlen- age 46.6±11.3 years) presenting to our department for cardi- dirme için başvuran 114 erkek hasta (ort. yaş 46.6±11.3) ologic evaluation. Hormonal analysis included serum levels alındı. Hormon analizlerinde serumda luteinize edici hor- of luteinizing hormone, prolactin, total testosterone (TT), free mon, prolaktin, total testosteron (TT), serbest testosteron, testosterone, estradiol (E2), and dehydroepiandrosterone östradiol (E2) ve dehidroepiandrosteron sülfat (DHEA-S) sulfate (DHEA-S). Parameters of HRV were derived from düzeyleri ölçüldü. Yirmi dört saatlik Holter kayıtlarından 24-hour Holter monitoring. The associations between serum KHD parametreleri hesaplandı. Serum cinsiyet steroidleri sex steroid levels and HRV parameters were investigated in ile KHD değerleri arasındaki ilişkiler hastalar üç yaş gru- three age groups (20-39 years; 40-59 years; >60 years). buna (20-39 yaş; 40-59 yaş; >60 yaş) ayrılarak incelendi.
    [Show full text]
  • Conjugated and Unconjugated Plasma Androgens in Normal Children
    Pediat. Res. 6: 111-118 (1972) Androstcncdionc sexual development dehydroepiandrosterone testosterone Conjugated and Unconjugated Plasma Androgens in Normal Children DONALD A. BOON,'291 RAYMOND E. KEENAN, W. ROY SLAUNWHITE, JR., AND THOMAS ACETO, JR. Children's Hospital, Medical Foundation of Buffalo, Roswell Park Memorial Institute, and Departments of Biochemistry and Pediatrics, School of Medicine, State University of New York at Buffalo, Buffalo, New York, USA Extract Methods developed in this laboratory permit measurement of the androgens, testos- terone (T), dehydroepiandrosterone (D), and androstenedione (A) on a 10-ml sample of plasma. We have determined concentrations of the unconjugated androgens (T, A, D) as well as of the sulfates of dehydroepiandrosterone (DS) and androsterone (AS) in the plasma of 85 healthy children of both sexes from birth through the age of 20 years. Our results are shown and summarized, along with those of other investigators. Mean plasma concentrations Sex and age ng/100 ml Mg/100 ml T A D AS DS Male Neonates 39 24 30 None detectable None detectable 1-8 years 25 58 64 2 11 9-20 years 231 138 237 28 74 Female Neonates 36 30 83 None detectable None detectable 1-8 years 11 69 54 5 20 9-20 years 28 84 164 22 44 Testosterone was elevated in both sexes in the newborn as compared with the 1-8- year-old group. In contrast, sulfated androgens, with one exception, were undetectable early in life. In males, there was a marked rise in all androgens, especially T, in the 9-18-year-old group.
    [Show full text]
  • Investigation About the Effects and the Detection of Finasteride, a Substance Which Can Be Misused As Masking Agent in Doping Control” W
    PROJECT SUMMARY “Investigation about the effects and the detection of finasteride, a substance which can be misused as masking agent in doping control” W. Schanzer, H. Geyer (German Sport University, Cologne, Germany) Finasteride is an inhibitor of 5-alpha reductase, the enzyme responsible for conversion of testosterone to dihydrotestosterone. It is administered orally in a dose of 5 mg daily for the treatment of benign prostatic hypertrophy. Since 1999 it is also admitted in several countries for the treatment of men with hair loss (androgenetic alopecia) and it seems to become a so called ,,life style drug”. The recommended dose for the treatment of hair loss is 1 mglday. Recent studies with finasteride have shown, that this substance can be misused as a potential masking agent. The application of finasteride may prevent the detection of misuse of anabolic-androgenic steroids like nandrolone, norandrostendione, norandrostenediols, dihydrotestosterone and testosterone. These preliminary results should be confirmed by more extensive studies with several volunteers. If the preliminary results can be confirmed, it should be discussed, if finasteride is added to the prohibited class of masking agents. The second aim of the study is to develop and validate a sensitive and specific method for the detection of finasteride misuse. Investigation about the effects and the detection of finasteride, a substance which can be misused as masking agent in doping control Results and conclusions Finasteride is an inhibitor of 5-alpha reductase and used for the treatment of benign prostatic hypertrophy and androgenetic alopecia. Investigations with finsteride with only one volunteer have shown, that the use of finasteride complicates the detection of the misuse of several anabolic steroids in doping control.
    [Show full text]
  • Mass Spec Testing for Steroid Hormone Profiles: Making an Impact on Patient Care
    Mass Spec Testing for Steroid Hormone Profiles: Making an Impact on Patient Care R.J. Singh, Ph.D. Mayo Clinic Objectives •Congenital Adrenal Hyperplasia (CAH) •Sex Steroids •Cushing’s CAH New Born Screening 1 CAH CholesterolBiosynthesis of Steroids Pregnenolone 17- OH Pregnenolone DHEA ase ’ -----------------------------------------------------------------------------3SDH 17,20 desmolase 17 OH Progesterone 17-OH Progesterone Androstenedione 21 OH'ase 17b SDH ---------------------------------------------- Aromatase 21-Deoxycorti- 11-deoxycortisol Testosterone costerone 11 OH'ase Aromatase ---------------------------------------------- Estrone Corticosterone Cortisol Estradiol 17b SDH 18 OH'ase ---------------------- Cortisone --- Aldosterone STEROID PROFILE BY LC MS/MS TIC: from 051200-36 9.5e5 8 9.0e5 1. Cortisone 8.5e5 2. Cortisol, Cortisol d-4 8.0e5 3. 21-Deoxycortisol 4. Corticosterone 7.5e5 5. 11-Deoxycortisol 7.0e5 6. Androstendione 6.5e5 7. DOC 8. 17-Hydroxyprogesterone 6.0e5 17-Hydroxypregnenolone 5.5e5 9. Progesterone 5.0e5 10. Pregnenolone Intensity, cps 4.5e5 4.0e5 3.5e5 3.0e5 6 2.5e5 5 7 10 2.0e5 1.5e5 34 2 1.0e5 1 5.0e4 9 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 Time, min 6 2 Basics of MS Method Basics of MS Method Lack of Standardization 3 RIA vs. LC-MS/MS 14000 12000 10000 8000 6000 4000 Mayo LC/MS/MS ng/dL LC/MS/MS Mayo 2000 0 0 2000 4000 6000 8000 10000 12000 14000 Ext/RIA ng/dL Correlation Between Two Sites 4 Bland Altman Plot (N=76) 1000 + 2 SD = 801.4 500 + 1 SD = 405.8 Mean difference= 10.1 0 (ng/dL) - 1 SD = 385.6 -500
    [Show full text]
  • A-1-Antitrypsin Deficiency: Phenotype Vs. Genotype
    Impact of Tandem Mass Spectrometry in Clinical Diagnostics R.J. Singh, Ph.D. Mayo Clinic Definition Diagnosis or Di`ag`nos´tics • Identification of a disease, disorder, or syndrome through a method of consistent and accurate analysis. Laboratory Automation Picture of the UVA lab here Methodologies for Analysis RIA GC-FID CLIA LC-UV/EC ELISA GC-MS FIA LC-MS ICMA LC-MS/MS Biosynthesis of Steroids Cholesterol Pregnenolone 17- OH Pregnenolone DHEA ---------------------3βSDH -------------------------------------------------------- 17,20 desmolase 17 OH’ase Progesterone 17-OH Progesterone Androstenedione 21 OH'ase 17b SDH ---------------------------------------------- Aromatase ------ 11-Deoxycorticosterone 11-deoxycortisol Testosterone 11 OH'ase Aromatase ---------------------------------------------- ------ Estrone Corticosterone Cortisol Estradiol 17b SDH 18 OH'ase ---------------------- Cortisone --- Aldosterone Cushing’s Syndrome Introduction Hypothalamus CRH Pituitary Cortisol ACTH - + Adrenal Gland Cortisol ACTH-Dependent Cushing’s Syndrome Cushing’s Disease Ectopic ACTH Syndrome ACTH-Independent Cushing’s Syndrome Adrenal adenoma Adrenal carcinoma Adrenal Gland Adrenaline Adrenal Cortex (outer) Adrenal Medulla (center) http://www.pathology.vcu.edu/education/endocrine/endocrine/adrenal/micro/adrad1x.gif Obesity Trends* Among U.S. Adults BRFSS, 1990, 1998, 2006 (*BMI ≥30, or about 30 lbs. overweight for 5’4” person) 1990 1998 2006 No Data <10% 10%–14% 15%–19% 20%–24% 25%–29% ≥30% Biosynthesis of Steroids Cholesterol Pregnenolone 17- OH
    [Show full text]
  • Memory-Enhancing Effects in Male Mice of Pregnenolone and Steroids Metabolically Derived from It
    Proc. Nati. Acad. Sci. USA Vol. 89, pp. 1567-1571, March 1992 Neurobiology Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it (memory enhancement/pregnenolone sulfate/receptors/immediate-early genes/aging) JAMES F. FLOOD*t, JOHN E. MORLEY*, AND EUGENE ROBERTSt§ *Genatnc Research Education and Clinical Center, Veterans Administration Medical Center, St. Louis, MO 63106, and St. Louis University School of Medicine, Division of Geriatric Medicine, St. Louis, MO 63104; and tDepartment of Neurobiochemistry, Beckman Research Institute of the City of Hope, Duarte, CA 91010 Contributed by Eugene Roberts, November 8, 1991 ABSTRACT Immediate post-training intracerebroven- postmitotic differentiated states was favored in both neurons tricular administration to male mice of pregnenolone (P), and glia (7, 8). pregnenolone sulfate (PS), dehydroepiandrosterone (DHEA), The water-soluble DHEAS, administered intracerebro- dehydroepiandrosterone sulfate (DHEAS), androstenedione, ventricularly (i.c.v.) or subcutaneously (s.c.) after training, testosterone, dihydrotestosterone, or aldosterone caused im- showed convincing memory-enhancing (ME) effects in foot- provement ofretention for footshock active avoidance training, shock active avoidance training (FAAT) in undertrained male while estrone, estradiol, progesterone, or 16.8-bromoepi- mice. DHEAS administered i.c.v. facilitated retention for androsterone did not. Dose-response curves were obtained for step-down passive avoidance training. Retention of FAAT P, PS, DHEA, and testosterone. P and PS were the most potent, was improved when DHEAS was given in taste-camouflaged PS showing significant effects at 3.5 fmol per mouse. The active drinking water for 1 week before and 1 week after training, steroids did not show discernible structural features or known while DHEAS in the drinking water for 2 weeks did not membrane or biochemical effects that correlated with their improve acquisition (9).
    [Show full text]